A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes (Q43997796)

28 November 2017

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes (English)

1 reference

28 November 2017

1 reference

1 reference

Robert Wilson

1

1 reference

28 November 2017

Jerome J Schentag

2

1 reference

28 November 2017

Peter Ball

3

1 reference

28 November 2017

Lionel Mandell

4

1 reference

28 November 2017

068 Study Group

5

1 reference

28 November 2017

1 April 2002

1 reference

28 November 2017

Clinical Therapeutics

1 reference

28 November 2017

24

1 reference

28 November 2017

4

1 reference

28 November 2017

639-652

1 reference

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Treatment of acute exacerbations of chronic bronchitis: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Future antibiotic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Acute exacerbations of chronic bronchitis: an international comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Use of quinolones for the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Treatment cost of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Bacterial infection and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985139-6

7 January 2021

10.1016/S0149-2918(02)85139-6

Identifiers

DOI

1 reference

28 November 2017

1 reference